Latest News

NMC has strategically designed these accreditation programs to address the diverse healthcare requirements of this growing community, ensuring accessible, high-quality care for every generation—from newborns to seniors.

Anktiva operates through a novel mechanism by binding to the interleukin-15 (IL-15) receptor, which triggers the proliferation and activation of natural killer cells, CD4+ cells, CD8+ cells, and memory T cells.

AbelZeta will receive up to USD630 million from AstraZeneca, with the payment structure including both upfront cash and milestone fees tied to the GPC3 program’s progress in China.

Surgeons successfully removed the entire tumor while carefully preserving its extremely fragile capsule intact.

The Board’s decision to extend Dr. Zoëga’s appointment reflects confidence in both his individual leadership and the broader executive team’s capabilities.

Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.

The U.S. Food and Drug Administration (FDA) recently approves an updated label for UNLOXCYT based on long-term follow-up data from the pivotal CK-301-101 clinical trial.

The company recently filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its first BFS-based prefilled injection device, achieving a major regulatory breakthrough for the platform.

This collaboration delivers crucial funding to Agenus while simultaneously securing sustained biologics manufacturing capacity within the United States.

Rezūm targets benign prostatic hyperplasia (BPH), a common non-cancerous condition where the prostate gland enlarges and disrupts urinary function in many men.